12.03.2015
- Bayer aims to achieve strong sales and earnings growth for its life science businesses in the coming years, CEO Marijn Dekkers said at the "Meet Management" investor conference in...
17.12.2014
- Bayer's Eylea (VEGF Trap-Eye) is not more effective than its competitor Lucentis to treat patients with diabetic macular edema, the German Institute for Quality and Efficiency in...
16.09.2014
- Roche's cancer drug Avastin as a cheaper treatment for wet age-related macular degeneration (wAMD), a leading cause of blindness in the elderly, does not appear to increase deaths...
29.05.2014
- As expected, Canadian drugmaker Valeant Pharmaceuticals International raised the cash component of its offer for Botox manufacturer Allergan on May 28. Its new offer values the US...
06.01.2014
- Bayer HealthCare has hit a stumbling block in the sales campaign for its new drug Eylea (aflibercept), or VEGF Trap-Eye, recommended for treatment of age-related wet macula...
30.07.2013
- Expectations that Bayer will embrace a trend in the pharma sector to split off non-core units may be too far ahead of the curve. The diversified German healthcare group has an...
07.05.2013
- Just two years ago, Regeneron Pharmaceuticals was a relatively obscure biotech company in the village of Tarrytown, a picturesque New York suburb better known for "Rip Van Winkle,"...
11.02.2013
- Regeneron Pharmaceuticals said its longtime drug-development partner Sanofi aims to boost its stake in the U.S. biotechnology company through open market purchases of its stock...
